Nicox S.A. to co promote Latanoprostene bunod in US with Bausch + Lomb for Glaucoma + Ocular Hypertension.
Nicox S.A. the international ophthalmic company, announced it has notified Bausch + Lomb (B+L), a division of Valeant Pharmaceuticals International, Inc., of its decision to exercise the option to co-promote latanoprostene bunod in the United States.
Latanoprostene bunod is a nitric oxide (NO)-donating prostaglandin F2-alpha analog in phase III clinical development for the potential treatment of Glaucoma and Ocular Hypertension which was licensed by Nicox to B+L in 2010. B+L�s phase III clinical program includes two studies, APOLLO and LUNAR, which are pivotal for registration in the US. Valeant recently said that it expects to receive top-line efficacy results from the first of these phase III studies in the third quarter of 2014, and from the second of these studies in the fourth quarter of 2014. Valeant also said latanoprostene bunod could be launched in the US in 2016, pending approval from the FDA.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins